Appointments

Gland Pharma appoints Ajay Sahni as CEO of Singapore subsidiary

Article cover image

Sahni brings over three decades of leadership experience across the fast-moving consumer goods (FMCG) and pharmaceutical industries.

Gland Pharma has appointed Ajay Sahni as Chief Executive Officer of Gland Pharma International Pte., its wholly owned subsidiary in Singapore, effective November 2, 2026.


In addition to leading the Singapore subsidiary, Sahni will oversee the operations of Cenexi, a wholly owned step-down subsidiary of Gland Pharma. He will report directly to the CEO of Gland Pharma, the Hyderabad-based pharmaceutical company said in a regulatory filing dated October 30.


Sahni brings more than 36 years of experience across the fast-moving consumer goods (FMCG) and pharmaceutical industries, with expertise spanning financial management, business development and general management.


Over the course of his career, he has held several senior leadership positions, including Finance Director, Project Manager – Business Development, Director of Financial Control, Planning and Analysis, Regional Finance Director for South and South-East Asia, President and Managing Director.


His previous organisations include Sanofi SA, Sanofi-Synthelabo Inc., Sanofi-Synthelabo Pte., Ferring Pharmaceuticals and Wockhardt France SAS. He has also held leadership responsibilities across subsidiaries such as Laboratoires Negma SAS, Wockhardt Bio AG and Pinewood Healthcare.


Before joining Gland Pharma, Sahni served as Managing Director of Pinewood Healthcare in Ireland and Wockhardt Bio AG in Switzerland. He also served as President of Wockhardt France SAS and its subsidiaries.


His international experience spans France, Belgium, Ireland, Switzerland, Singapore and the United States. Sahni holds a Bachelor's degree in Business Administration from the European University of Brussels, Belgium.

Loading...